Fostamatinib disodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for fostamatinib disodium and what is the scope of freedom to operate?
Fostamatinib disodium
is the generic ingredient in one branded drug marketed by Rigel Pharms and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fostamatinib disodium has one hundred and eighteen patent family members in forty-five countries.
One supplier is listed for this compound.
Summary for fostamatinib disodium
International Patents: | 118 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 112 |
Clinical Trials: | 19 |
Patent Applications: | 518 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for fostamatinib disodium |
DailyMed Link: | fostamatinib disodium at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for fostamatinib disodium
Generic Entry Date for fostamatinib disodium*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for fostamatinib disodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rigel Pharmaceuticals | Phase 3 |
AstraZeneca | Phase 2 |
AstraZeneca | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for fostamatinib disodium
Paragraph IV (Patent) Challenges for FOSTAMATINIB DISODIUM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TAVALISSE | Tablets | fostamatinib disodium | 100 mg and 150 mg | 209299 | 1 | 2022-04-18 |
US Patents and Regulatory Information for fostamatinib disodium
International Patents for fostamatinib disodium
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 102090440 | ⤷ Try for Free | |
Eurasian Patent Organization | 028432 | НОВЫЕ СОСТАВЫ НА ОСНОВЕ (ТРИМЕТОКСИФЕНИЛАМИНО)ПИРИМИДИНИЛОВ (NEW (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL FORMULATIONS) | ⤷ Try for Free |
China | 101115761 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | ⤷ Try for Free |
South Korea | 20190109576 | 신규한 피리미디닐 제형 (NEW TRIMETHOXYPHENYLAMINOPYRIMIDINYL FORMULATIONS) | ⤷ Try for Free |
Norway | 20074179 | ⤷ Try for Free | |
Slovenia | 2217241 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for fostamatinib disodium
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1856135 | PA2020507 | Lithuania | ⤷ Try for Free | PRODUCT NAME: FOSTAMATINIBO DINATRIO HEKSAHIDRATAS; REGISTRATION NO/DATE: EU/1/19/1405 20200109 |
1856135 | 2020/017 | Ireland | ⤷ Try for Free | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
1856135 | 122020000021 | Germany | ⤷ Try for Free | PRODUCT NAME: FOSTAMATINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT UND/ODER SOLVAT DAVON, INSBESONDERE DINATRIUM-FOSTAMATINIB-HEXAHYDRAT; REGISTRATION NO/DATE: EU/1/19/1405 20200109 |
1856135 | SPC/GB20/016 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTERED: UK EU/1/19/1405 (NI) 20200113; UK PLGB 12930/0022 20200113; UK PLGB 12930/0023 20200113 |
1856135 | LUC00153 | Luxembourg | ⤷ Try for Free | PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113 |
1856135 | CA 2020 00018 | Denmark | ⤷ Try for Free | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Fostamatinib Disodium
More… ↓